Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies
Authors
Keywords
-
Journal
NATURE REVIEWS DRUG DISCOVERY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-31
DOI
10.1038/s41573-023-00807-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR
- (2023) Evangelia Kokalaki et al. MOLECULAR THERAPY
- A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
- (2023) Christoph K. Stein-Thoeringer et al. NATURE MEDICINE
- Rapid manufacturing of non-activated potent CAR T cells
- (2022) Saba Ghassemi et al. Nature Biomedical Engineering
- CD19/22 CAR T-cells in Children and Young Adults with B-ALL: Phase I Results and Development of a Novel Bicistronic CAR
- (2022) Haneen Shalabi et al. BLOOD
- CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
- (2022) Kevin Pan et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- The tricks for fighting against cancer using CAR NK cells: A review
- (2022) Fatemeh Vahidian et al. MOLECULAR AND CELLULAR PROBES
- CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours
- (2022) Rebecca C. Larson et al. NATURE
- PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial
- (2022) Vivek Narayan et al. NATURE MEDICINE
- Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
- (2022) Melody Smith et al. NATURE MEDICINE
- Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial
- (2022) Sattva S. Neelapu et al. NATURE MEDICINE
- Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie’s choice for patients with relapsed refractory multiple myeloma
- (2022) James Davis et al. Expert Review of Hematology
- Next-Generation CAR T-cell Therapies
- (2022) Regina M. Young et al. Cancer Discovery
- CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities
- (2022) Lionel A. Kankeu Fonkoua et al. Molecular Therapy-Oncolytics
- Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion
- (2022) Diana Gumber et al. EBioMedicine
- CAR-NK cells for cancer immunotherapy: from bench to bedside
- (2022) Leisheng Zhang et al. Biomarker Research
- Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia
- (2022) Saar I Gill et al. Blood Advances
- Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
- (2022) Thomas Martin et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated results of a multicenter first-in-human study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM).
- (2022) Juan Du et al. JOURNAL OF CLINICAL ONCOLOGY
- Lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Primary analysis from the phase 2 PILOT study.
- (2022) Alison Sehgal et al. JOURNAL OF CLINICAL ONCOLOGY
- Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study
- (2022) Michael Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Antigen glycosylation regulates efficacy of CAR T cells targeting CD19
- (2022) Amanda Heard et al. Nature Communications
- Modulation of BCL-2 in both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T cell Immunotherapy against Cancer
- (2022) Yong Gu Lee et al. Cancer Discovery
- Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
- (2022) Nathalie Scholler et al. NATURE MEDICINE
- UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial
- (2022) Reuben Benjamin et al. Lancet Haematology
- CD22 CAR T Cells Demonstrate Favorable Safety Profile and High Response Rates in Pediatric and Adult B-ALL: Results of a Phase 1b Study
- (2022) Nikeshan Jeyakumar et al. BLOOD
- Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial
- (2022) Tianyi Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
- (2022) Theodore W. Laetsch et al. JOURNAL OF CLINICAL ONCOLOGY
- CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naïve/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
- (2022) Sarah M. Larson et al. Cancer Discovery
- A critical role for fas-mediated off-target tumor killing in T cell immunotherapy
- (2021) Ranjan Upadhyay et al. Cancer Discovery
- The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression
- (2021) Almudena García-Ortiz et al. Cancers
- Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
- (2021) John H. Baird et al. Blood Advances
- Tumor interferon signaling and suppressive myeloid cells associate with CAR T cell failure in large B cell lymphoma
- (2021) Michael D. Jain et al. BLOOD
- Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy
- (2021) Elise A. Chong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy
- (2021) Tracy Rabilloud et al. Nature Communications
- KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
- (2021) Bijal D Shah et al. BLOOD
- Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia
- (2021) Marie-Emilie Dourthe et al. LEUKEMIA
- Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells
- (2021) Nathan Singh et al. NATURE MEDICINE
- Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
- (2021) Evan W. Weber et al. SCIENCE
- Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma
- (2021) Gloria Iacoboni et al. Cancer Medicine
- The Complexity of the Tumor Microenvironment and Its Role in Acute Lymphoblastic Leukemia: Implications for Therapies
- (2021) Carolina Simioni et al. Frontiers in Oncology
- A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity
- (2021) Morgane Boulch et al. Science Immunology
- Overcoming Intrinsic Resistance of Cancer Cells to CAR T-Cell Killing
- (2021) Jean Lemoine et al. CLINICAL CANCER RESEARCH
- Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.
- (2021) Larry D. Anderson et al. JOURNAL OF CLINICAL ONCOLOGY
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
- (2021) Jesus G Berdeja et al. LANCET
- Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study
- (2021) Stephen J Schuster et al. LANCET ONCOLOGY
- Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial
- (2021) Yajing Zhang et al. LEUKEMIA
- CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
- (2021) Jay Y. Spiegel et al. NATURE MEDICINE
- Gene-Edited Interleukin CAR-T Cells Therapy in the Treatment of Malignancies: Present and Future
- (2021) Zhengchao Zhang et al. Frontiers in Immunology
- PI3K/Akt Pathway: The Indestructible Role of a Vintage Target as a Support to the Most Recent Immunotherapeutic Approaches
- (2021) Matteo Caforio et al. Cancers
- Effective anti-BCMA retreatment in multiple myeloma
- (2021) Nicolas Gazeau et al. Blood Advances
- Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
- (2021) Tanya Siddiqi et al. BLOOD
- A Multicenter Analysis of Outcomes, Toxicities, and Patterns of Use with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas
- (2021) Peter A. Riedell et al. BLOOD
- CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed/Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma
- (2021) Natalie S Grover et al. BLOOD
- Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)
- (2021) Caron Jacobson et al. BLOOD
- CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL
- (2021) Noelle V Frey et al. BLOOD
- Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
- (2021) Caron A Jacobson et al. LANCET ONCOLOGY
- PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells
- (2021) Young-Ho Lee et al. MOLECULAR THERAPY
- Off-the-shelf, gene-edited CAR-T cells forge ahead, despite safety scare
- (2021) Cormac Sheridan NATURE BIOTECHNOLOGY
- Engineering CAR-T cells to activate small-molecule drugs in situ
- (2021) Thomas J. Gardner et al. Nature Chemical Biology
- CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial
- (2021) Shaun Cordoba et al. NATURE MEDICINE
- CAR-NK Cells: From Natural Basis to Design for Kill
- (2021) Muhammad Babar Khawar et al. Frontiers in Immunology
- T-cell intrinsic Toll-like receptor signaling: implications for cancer immunotherapy and CAR T-cells
- (2021) Yasmin Nouri et al. Journal for ImmunoTherapy of Cancer
- Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)
- (2020) Marcelo C. Pasquini et al. BLOOD
- Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma
- (2020) Andrew J. Cowan et al. BLOOD
- Infusion of chimeric antigen receptor T cells against dual targets of CD19 and B-cell maturation antigen for the treatment of refractory multiple myeloma
- (2020) Fang Tang et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
- (2020) Enli Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- CRISPR-engineered T cells in patients with refractory cancer
- (2020) Edward A. Stadtmauer et al. SCIENCE
- Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T cell dysfunction
- (2020) Nathan Singh et al. Cancer Discovery
- CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
- (2020) Nirali N. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
- (2020) Loretta J. Nastoupil et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia
- (2020) Noelle V. Frey et al. JOURNAL OF CLINICAL ONCOLOGY
- CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression
- (2020) Kristen Fousek et al. LEUKEMIA
- Human chimeric antigen receptor macrophages for cancer immunotherapy
- (2020) Michael Klichinsky et al. NATURE BIOTECHNOLOGY
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tuning the Antigen Density Requirement for CAR T-cell Activity
- (2020) Robbie G. Majzner et al. Cancer Discovery
- Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity
- (2020) Caron A. Jacobson et al. JOURNAL OF CLINICAL ONCOLOGY
- Engineered off-the-shelf therapeutic T cells resist host immune rejection
- (2020) Feiyan Mo et al. NATURE BIOTECHNOLOGY
- Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
- (2020) Wei Sang et al. Cancer Medicine
- CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
- (2020) Alba Rodriguez-Garcia et al. Frontiers in Immunology
- Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant
- (2020) Prashant Sharma et al. Blood Advances
- Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells
- (2020) May Daher et al. BLOOD
- CD19-Specific CAR-T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor is Effective in Patients with PD-L1 Positive B-Cell Lymphoma
- (2020) Hui Liu et al. CLINICAL CANCER RESEARCH
- Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
- (2020) Kathryn M. Cappell et al. JOURNAL OF CLINICAL ONCOLOGY
- A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy
- (2020) Shannon K. Oda et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
- (2020) Nirav N. Shah et al. NATURE MEDICINE
- Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy
- (2020) Zhen Zhang et al. Journal for ImmunoTherapy of Cancer
- Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
- (2020) Frederick L. Locke et al. Blood Advances
- Macrophage-based approaches for cancer immunotherapy
- (2020) Nicholas R. Anderson et al. CANCER RESEARCH
- Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
- (2020) Reuben Benjamin et al. LANCET
- Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15
- (2019) Yuhui Chen et al. CLINICAL CANCER RESEARCH
- NR4A transcription factors limit CAR T cell function in solid tumours
- (2019) Joyce Chen et al. NATURE
- T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy
- (2019) Tori N. Yamamoto et al. JOURNAL OF CLINICAL INVESTIGATION
- Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR-T cells
- (2019) Kevin A. Hay et al. BLOOD
- Induction of human pluripotent stem cell-derived natural killer cells for immunotherapy under chemically defined conditions
- (2019) Hiroyuki Matsubara et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T cell efficacy
- (2019) Jaco A. C. van Bruggen et al. BLOOD
- B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
- (2019) Adam D. Cohen et al. JOURNAL OF CLINICAL INVESTIGATION
- Cytopenia following axicabtagene ciloleucel (axi-cel) for refractory large B-cell lymphoma (LBCL).
- (2019) Jennifer Marilyn Logue et al. JOURNAL OF CLINICAL ONCOLOGY
- 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies
- (2019) Yingxi Xu et al. Journal of Hematology & Oncology
- CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
- (2019) Bryan D. Choi et al. NATURE BIOTECHNOLOGY
- The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
- (2019) Katrin Mestermann et al. Science Translational Medicine
- T Cell Dysfunction in Cancer Immunity and Immunotherapy
- (2019) Anliang Xia et al. Frontiers in Immunology
- Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
- (2019) Marijke Timmers et al. Frontiers in Immunology
- γ-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
- (2019) Margot J. Pont et al. BLOOD
- Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma
- (2019) Zixun Yan et al. CLINICAL CANCER RESEARCH
- Toxicity and Response following CD19-specific CAR T cells in pediatric/young adult relapsed/refractory B-ALL
- (2019) Kevin J. Curran et al. BLOOD
- Superior Efficacy of CAR-T Cells Using Marrow-Infiltrating Lymphocytes (MILsTM) As Compared to Peripheral Blood Lymphocytes (PBLs)
- (2019) Eric R. Lutz et al. BLOOD
- Efficacy and Safety of CAR19/22 T-cell "Cocktail" Therapy in Patients with Refractory/ Relapsed B-Cell Malignancies
- (2019) Na Wang et al. BLOOD
- A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial
- (2019) Zhiling Yan et al. Lancet Haematology
- Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment
- (2019) Yangjing Zhao et al. Cellular & Molecular Immunology
- Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia
- (2019) Noelle V. Frey et al. JOURNAL OF CLINICAL ONCOLOGY
- c-Jun overexpression in CAR T cells induces exhaustion resistance
- (2019) Rachel C. Lynn et al. NATURE
- Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Role and Prognosis
- (2019) Alexandra Ioana Cioroianu et al. Analytical Cellular Pathology
- Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells associate with clinical outcomes in NHL
- (2018) John Rossi et al. BLOOD
- T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
- (2018) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy
- (2018) Shivani Srivastava et al. JOURNAL OF IMMUNOLOGY
- Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells
- (2018) Wei Xiong et al. MOLECULAR THERAPY
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
- (2018) Joseph A. Fraietta et al. NATURE MEDICINE
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity
- (2018) A. J. Davenport et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System
- (2018) Mauro P. Avanzi et al. Cell Reports
- Chimeric antigen receptors that trigger phagocytosis
- (2018) Meghan A Morrissey et al. eLife
- CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity
- (2018) Gray Kueberuwa et al. Molecular Therapy-Oncolytics
- CD19 alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulum
- (2018) Asen Bagashev et al. MOLECULAR AND CELLULAR BIOLOGY
- Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
- (2018) Sarwish Rafiq et al. NATURE BIOTECHNOLOGY
- Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
- (2018) Marco Ruella et al. NATURE MEDICINE
- Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
- (2018) Elena J. Orlando et al. NATURE MEDICINE
- Checkpoint blockade reverses anergy in IL13Rα2 humanized scFv based CAR T cells to treat murine and canine gliomas.
- (2018) Yibo Yin et al. Molecular Therapy-Oncolytics
- Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function
- (2018) Eric Shifrut et al. CELL
- Functional Improvement of Chimeric Antigen Receptor Through Intrinsic Interleukin-15Ra Signaling
- (2018) Sushmita Nair et al. CURRENT GENE THERAPY
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
- (2018) Haiying Qin et al. Molecular Therapy-Oncolytics
- Allogeneic CAR-T Cells: More than Ease of Access?
- (2018) Charlotte Graham et al. Cells
- Ibrutinib treatment improves T cell number and function in CLL patients
- (2017) Meixiao Long et al. JOURNAL OF CLINICAL INVESTIGATION
- CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis
- (2017) Jeannette Fischer et al. JOURNAL OF IMMUNOTHERAPY
- Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity
- (2017) E Liu et al. LEUKEMIA
- Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells
- (2017) Daniel T. MacLeod et al. MOLECULAR THERAPY
- Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
- (2017) Justin Eyquem et al. NATURE
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exhaustion-associated regulatory regions in CD8+tumor-infiltrating T cells
- (2017) Giuliana P. Mognol et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells
- (2017) Marco Ruella et al. Cancer Discovery
- Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
- (2017) Thomas Shum et al. Cancer Discovery
- CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
- (2017) Levi J. Rupp et al. Scientific Reports
- An oxygen sensitive self-decision making engineered CAR T-cell
- (2017) Alexandre Juillerat et al. Scientific Reports
- PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity
- (2017) Maria Gato-Cañas et al. Cell Reports
- Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18
- (2017) Biliang Hu et al. Cell Reports
- Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade
- (2017) Inna Serganova et al. Molecular Therapy-Oncolytics
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
- (2016) S. A. Ali et al. BLOOD
- Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking
- (2016) Friederike Braig et al. BLOOD
- PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR
- (2016) Elise A. Chong et al. BLOOD
- Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
- (2016) R. Gardner et al. BLOOD
- Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
- (2016) Joseph A. Fraietta et al. BLOOD
- Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections
- (2016) R J O'Reilly et al. BONE MARROW TRANSPLANTATION
- Chronic graft versus host disease burden and late transplant complications are lower following adult double cord blood versus matched unrelated donor peripheral blood transplantation
- (2016) J A Gutman et al. BONE MARROW TRANSPLANTATION
- A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
- (2016) Xiaojun Liu et al. CANCER RESEARCH
- The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma
- (2016) M. Ruella et al. CLINICAL CANCER RESEARCH
- Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis
- (2016) Andrea Schietinger et al. IMMUNITY
- Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
- (2016) Leonid Cherkassky et al. JOURNAL OF CLINICAL INVESTIGATION
- Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
- (2016) Marco Ruella et al. JOURNAL OF CLINICAL INVESTIGATION
- CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
- (2016) Elad Jacoby et al. Nature Communications
- Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies
- (2016) Marco Ruella et al. Computational and Structural Biotechnology Journal
- Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies
- (2015) Laurent Poirot et al. CANCER RESEARCH
- TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
- (2015) Joe-Marc Chauvin et al. JOURNAL OF CLINICAL INVESTIGATION
- Memory T cell–driven differentiation of naive cells impairs adoptive immunotherapy
- (2015) Christopher A. Klebanoff et al. JOURNAL OF CLINICAL INVESTIGATION
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy
- (2015) Julien Valton et al. MOLECULAR THERAPY
- γ-secretase directly sheds the survival receptor BCMA from plasma cells
- (2015) Sarah A. Laurent et al. Nature Communications
- Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
- (2015) E. Sotillo et al. Cancer Discovery
- IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumorsin vivo
- (2015) Mythili Koneru et al. OncoImmunology
- The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
- (2014) Robert J. Johnston et al. CANCER CELL
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
- (2013) J. A. Dubovsky et al. BLOOD
- Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation
- (2013) A. M. Leen et al. BLOOD
- Interleukin-7 Mediates Selective Expansion of Tumor-redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition
- (2013) S. K. Perna et al. CLINICAL CANCER RESEARCH
- Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
- (2013) L. B. John et al. CLINICAL CANCER RESEARCH
- Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy
- (2013) Maria Themeli et al. NATURE BIOTECHNOLOGY
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses
- (2013) V. D. Fedorov et al. Science Translational Medicine
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Network Analysis Reveals Centrally Connected Genes and Pathways Involved in CD8+ T Cell Exhaustion versus Memory
- (2012) Travis A. Doering et al. IMMUNITY
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- CD28 Costimulation Impairs the Efficacy of a Redirected T-cell Antitumor Attack in the Presence of Regulatory T cells Which Can Be Overcome by Preventing Lck Activation
- (2011) David M Kofler et al. MOLECULAR THERAPY
- Microenvironment Determines Lineage Fate in a Human Model of MLL-AF9 Leukemia
- (2008) Junping Wei et al. CANCER CELL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More